For over 35 years, ARCS Australia has been bringing together a vibrant and diverse community of professionals working in academia, government, biotech and pharmaceutical companies, hospitals and healthcare settings and other organisations to showcase and support the development and regulation of therapeutic goods.
The annual conference was very well attended by delegates from a cross-section of the healthcare sector including clinical research, regulatory affairs, pharmacovigilance, medical affairs/MSLs, medical technology, health economics and quality/ GM, including senior executives through to recent graduates.
Content included sessions on cutting-edge topics and themes along with sessions containing critical changes in the professional landscape from governments, industry leaders and independent experts.
This year, Regulink presented on the changes that have taken place within the MHRA since Brexit for international companies, particularly focusing on new and exciting submission pathways that aim to place the UK at the forefront for medicinal product development and marketing, as well as discussing the valued role the UK plays with collaborative procedures such as ACCESS and ORBIS and the relatively new International Recognition Framework. This presentation was extremely well attended by professionals involved in regulatory affairs, manufacturing and quality/GMP and the wider business executive in the Asia Pacific region.
Additonally, Regulink hosted an educational session to expand in greater depth into MHRA procedures, with a focus on the strategies around importation into the UK for unlicensed medicines, for which Regulink has significant experience.
We can’t wait to go back in 2024 to continue to learn more about the exciting overseas markets in this region and share our experience working closely with the UK and EU.
You can view or download the ARCS 2023 presentations from the below links
2023 ARCS Conference – Post Brexit UK Innovation & Procedural Routes (1)
2023 ARCS Conference – Strategies for the importation of unlicensed medicines into the UK (1)
